- (-%)
Source:
We are a late-stage biotechnology company focused on the clinical development and commercialization of angiogenic gene therapy biotherapeutics for strategic niche markets primarily for the treatment of cardiovascular disease. Our technology platform is designed to biologically activate the human bodys innate angiogenic healing process to stimulate the growth of microvascular networks for patients with ischemic cardiovascular, cerebral, and other medical conditions and diseases, as well as for advanced tissue engineering applications.
Country | United States |
Headquarters | san diego, california |
Phone Number | (858) 436-1000 |
Industry | manufacturing |
CEO | /S/ Christopher J. Reinhard |
Website | genebiotherapeutics.com |